8
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Immune Checkpoint Inhibitor-Associated Cardiotoxicity: Current Understanding on Its Mechanism, Diagnosis and Management

      review-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Immune checkpoint inhibitors (ICIs) that target cytotoxic T lymphocyte antigen 4, programmed cell death-1, and PD-ligand 1 have revolutionized cancer treatment, achieving unprecedented efficacy in multiple malignancies. ICIs are increasingly being used in early cancer settings and in combination with various other types of therapies, including targeted therapy, radiotherapy, and chemotherapy. However, despite the excellent therapeutic effect of ICIs, these medications typically result in a broad spectrum of toxicity reactions, termed immune-related adverse events (irAEs). Of all irAEs, cardiotoxicity, uncommon but with high mortality, has not been well recognized. Herein, based on previous published reports and current evidence, we summarize the incidence, diagnosis, clinical manifestations, underlying mechanisms, treatments, and outcomes of ICI-associated cardiotoxicity and discuss possible management strategies. A better understanding of these characteristics is critical to managing patients with ICI-associated cardiotoxicity.

          Related collections

          Most cited references92

          • Record: found
          • Abstract: found
          • Article: not found

          Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma.

          : Melanoma tends to be refractory to various immunotherapies because of tumor-induced immunosuppression. To investigate the mechanism underlining the immunosuppression of melanoma patients, the authors focused on programmed cell death-1 (PD-1)/PD-1 ligand 1 (PD-L1) interaction between tumor cells and T cells. : Melanoma specimens were collected from 59 primary tumors, 16 lymph nodes, and 4 lesions of in-transit metastasis. Specimens stained with anti-PD-L1 monoclonal antibodies were digitalized to jpg files. To evaluate the intensity of PD-L1 expression, histograms were used, and the red density (RD) was measured. PD-1 expression on T cells was analyzed in blood samples from 10 patients who had stage IV melanoma and in 4 samples of in-transit metastases. : Twenty-five patients comprised the "low" PD-L1 expression group (RD value, or =90). Breslow tumor thickness in the high-expression group was significantly higher than in the low-expression group. Univariate and multivariate analyses revealed that the overall survival rate of the high-expression group was significantly lower than that of the low-expression group. In all patients with stage IV disease who were examined, both CD8-positive and CD4-positive T cells had significantly higher PD-1 expression levels in the peripheral blood. Tumor-infiltrating T cells expressed high levels of PD-1, and its expression was elevated further during the clinical course. : The current results indicated that there is a correlation between the degree of PD-L1 expression and the vertical growth of primary tumors in melanoma. Multivariate analysis demonstrated that PD-L1 expression is an independent prognostic factor for melanoma. Cancer 2010. (c) 2010 American Cancer Society.
            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America.

              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              Immune checkpoint inhibitors and cardiovascular toxicity

                Bookmark

                Author and article information

                Contributors
                Journal
                Front Pharmacol
                Front Pharmacol
                Front. Pharmacol.
                Frontiers in Pharmacology
                Frontiers Media S.A.
                1663-9812
                29 November 2019
                2019
                : 10
                : 1350
                Affiliations
                [1] 1Department of Biotherapy, Cancer Center, and National Clinical Research Center for Geriatrics, West China Hospital of Sichuan University , Chengdu, China
                [2] 2Department of Dermatovenerology, West China Hospital, Sichuan University , Chengdu, China
                [3] 3Department of Neurosurgery, West China Hospital, Sichuan University , Chengdu, China
                [4] 4West China School of Medicine, Sichuan University , Chengdu, China
                Author notes

                Edited by: Shuang Zhou, University of Houston, United States

                Reviewed by: Zhejian Ji, Harvard Medical School, United States; Feng Tian, Harvard Medical School, United States

                *Correspondence: Zhen-Yu Ding, dingzhenyu@ 123456scu.edu.cn ; Ji-Yan Liu, liujiyan1972@ 123456163.com

                This article was submitted to Pharmaceutical Medicine and Outcomes Research, a section of the journal Frontiers in Pharmacology

                Article
                10.3389/fphar.2019.01350
                6897286
                31849640
                7e353c6d-9c63-45bc-b95f-f06d3d9a10d2
                Copyright © 2019 Zhou, Zhu, Wang, Xie, Chen, Zhang, Xia, Ding and Liu

                This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

                History
                : 11 August 2019
                : 24 October 2019
                Page count
                Figures: 4, Tables: 2, Equations: 0, References: 137, Pages: 20, Words: 9972
                Categories
                Pharmacology
                Review

                Pharmacology & Pharmaceutical medicine
                immune checkpoint inhibitors,cardiotoxicity,myocarditis,pericarditis,cytotoxic t lymphocyte-associated antigen-4,programmed cell death protein 1,programmed cell death-ligand 1

                Comments

                Comment on this article